Loading
Paper cited by one technology page, one pathway page and one term page, indexed on Europe PMC as PubMed record 29180633 and published in Nature Communications; the citing pages link this DOI, which is how the record was matched.
Abiraterone treats metastatic castrate-resistant prostate cancer by inhibiting CYP17A, an enzyme for testosterone auto-production. With standard dosing, evolution of resistance with treatment failure (radiographic progression) occurs at a median of ~16.5 months. We hypothesize time to progression (TTP) could be increased by integrating evolutionary dynamics into therapy. We developed an evolutionary game theory model using Lotka-Volterra equations with three competing cancer "species": androgen dependent, androgen producing, and androgen independent. Simulations with standard abiraterone dosing demonstrate strong selection for androgen-independent cells and rapid treatment failure. Adaptive therapy, using patient-specific tumor dynamics to inform on/off treatment cycles, suppresses proliferation of androgen-independent cells and lowers cumulative drug dose. In a pilot clinical trial, 10 of 11 patients maintained stable oscillations of tumor burdens; median TTP is at least 27 months with reduced cumulative drug use of 47% of standard dosing. The outcomes show significant improvement over published studies and a contemporaneous population.
Indexed on Europe PMC as PubMed record 29180633 (DOI 10.1038/s41467-017-01968-5). Matched by DOI alone: one technology page, one pathway page and one term page cite this DOI among their external links (the pages are listed under Related), and this page was written so that the citation resolves inside OnCo. No figure has been checked by an editor.
One technology page, one pathway page and one term page on OnCo cite this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing pages listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
Shares Adaptive therapy (evolution-based dosing), Clonal evolution and the ecological view of cancer.
Shares Nature Communications, Clonal evolution and the ecological view of cancer, Prostate cancer.
Shares TRANSFORMER: bipolar androgen therapy versus enzalutamide in asymptomatic metastatic castration-resistant prostate cancer, Prostate cancer roadmap: from Huggins and the discovery that a cancer can depend on a hormone, through the PSA epidemic and what it cost, the androgen receptor drugs, the DNA repair subset and PSMA, to a 2032 registry watch, Prostate cancer.
Shares Nature Communications, Clonal evolution & minimal residual disease, Prostate cancer.
Shares Clonal evolution and the ecological view of cancer, Clonal evolution & minimal residual disease.
Shares Adaptive therapy (evolution-based dosing), Clonal evolution and the ecological view of cancer.
Shares Clonal evolution and the ecological view of cancer, Clonal evolution & minimal residual disease.
Shares The evolutionary history of lethal metastatic prostate cancer, Prostate cancer roadmap: from Huggins and the discovery that a cancer can depend on a hormone, through the PSA epidemic and what it cost, the androgen receptor drugs, the DNA repair subset and PSMA, to a 2032 registry watch, Prostate cancer.